A pharmacy that transfers controlled substances to another pharmacy or practitioner, whether to cover a shortage or fill an emergency request, is distributing under the Controlled Substances Act, an activity that ordinarily requires its own DEA distributor registration. 21 CFR 1307.11 lets a registrant that only holds a dispensing registration make those transfers without a separate distributor registration, but only up to a hard 5 percent ceiling. Cross that line without registering as a distributor and the pharmacy has engaged in unregistered distribution, exposing its registration to formal DEA action.
The Threshold and What Counts Toward It
Under 21 CFR 1307.11(a)(1)(iv), the total dosage units a pharmacy distributes to other practitioners during a calendar year cannot exceed 5 percent of the total dosage units of all controlled substances the pharmacy both distributes and dispenses that same year. The calculation runs on a rolling calendar-year basis, not per transaction, so a pharmacy with a heavy dispensing volume has more room before it trips the ceiling than a low-volume pharmacy that makes the same transfers. The receiving practitioner must independently hold a registration authorizing it to dispense that controlled substance, and distributions to automated dispensing systems at long-term care facilities are excluded from the calculation under 21 CFR 1307.11(c).
Recordkeeping and the Order Form Requirement
Every distribution made under the exception must be recorded by both the distributing and the receiving pharmacy under 21 CFR 1304.22(c), and the transfer has to reconcile against the pharmacy's own inventory reconciliation records rather than sit as an unexplained gap. For Schedule I or II substances, the transaction additionally requires a DEA Form 222 or an equivalent Controlled Substances Ordering System (CSOS) transaction under Part 1305; an invoice or verbal confirmation between pharmacists does not satisfy this requirement. A pharmacy that cannot produce matching order-form and dosage-unit records for a transfer has handed a DEA diversion investigator the exact gap the 5 percent rule was built to close.
Suspicious Order Monitoring Still Applies
Operating inside the 5 percent exception does not exempt a pharmacy from the suspicious order monitoring duties that 21 CFR 1301.74(b) imposes on non-practitioner registrants. A pharmacy distributing under 21 CFR 1307.11 is still expected to design a system that flags orders of unusual size, pattern, or frequency and to report qualifying orders, the same standard DEA applies to full distributor registrants under its suspicious order monitoring framework. A pharmacy that treats its outbound transfers as informal favors between colleagues, with no monitoring system behind them, is already out of step with what DEA expects of any registrant moving product downstream.
The Consequence of Exceeding the Threshold
A pharmacy that anticipates exceeding the 5 percent ceiling is required under 21 CFR 1307.11(b) to obtain a distributor registration before it does. Distributing beyond the threshold without that registration is unregistered distribution of a controlled substance, a Controlled Substances Act violation independent of whether any single transfer was itself improper. DEA's administrative response can range from a formal order to show cause seeking revocation or denial of the pharmacy's registration up to an immediate suspension order where DEA concludes the pharmacy's conduct presents an imminent danger to public health or safety. These findings surface most often during a routine DEA inspection or a records audit, once an investigator sets a pharmacy's total outbound dosage units against its dispensing volume for the year.
A pharmacy that transfers controlled substances to another pharmacy without a distributor registration is engaged in unregistered distribution the moment its dosage units cross five percent of what it dispensed and distributed that year.
Why Early Legal Counsel Is Critical
It is critical that pharmacies promptly retain experienced healthcare defense counsel upon receiving a DEA subpoena, an order to show cause, or any other inquiry into controlled substance distribution activity. Early legal intervention can protect the pharmacy's registration, ensure the response addresses both the distribution recordkeeping and the suspicious order monitoring questions DEA investigators typically raise, avoid inadvertent admissions, and preserve defenses that may otherwise be lost. Delaying representation can significantly affect the outcome of the matter.
How Health Law Alliance Can Help
Health Law Alliance defends pharmacies against DEA registration actions tied to controlled substance distribution, including 5 percent threshold disputes and suspicious order monitoring findings. Our bench includes a former federal prosecutor and a former senior healthcare compliance executive, background that shapes how we evaluate whether flagged distributions are defensible. If your pharmacy has received a DEA inquiry involving transfers to another pharmacy or practitioner, contact us for a free, confidential consultation.
